Anna W Ma Selected Research

7- (4- (3- ethynylphenylamino)- 7- methoxyquinazolin- 6- yloxy)- N- hydroxyheptanamide

4/2015	A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma.
6/2013	Potential advantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anna W Ma Research Topics

Disease

2	Neoplasms (Cancer) 01/2017 - 06/2013
1	Carcinoma (Carcinomatosis) 01/2017
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2017
1	Squamous Cell Carcinoma of Head and Neck 04/2015
1	Squamous Cell Neoplasms (Squamous Cell Cancer) 04/2015
1	Stomach Neoplasms (Stomach Cancer) 06/2013
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 06/2013

Drug/Important Bio-Agent (IBA)

2	Histone Deacetylases (Histone Deacetylase)IBA 01/2017 - 04/2015
2	7- (4- (3- ethynylphenylamino)- 7- methoxyquinazolin- 6- yloxy)- N- hydroxyheptanamideIBA 04/2015 - 06/2013
1	Proteins (Proteins, Gene)FDA Link 01/2017
1	CUDC-907IBA 01/2017
1	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2017
1	ErbB Receptors (EGF Receptor)IBA 04/2015
1	Cisplatin (Platino)FDA LinkGeneric 04/2015
1	Growth Factor ReceptorsIBA 04/2015
1	Cadherins (E-Cadherin)IBA 06/2013

Therapy/Procedure

1	Therapeutics 01/2017
1	Radiotherapy 04/2015